Dendritic cell-based immunotherapy - implications for novel vaccines from transgenic hSIGN and HUT9 mice
2009
Dendritic cell receptors represent attractive targets for vaccination. In this work a conventional transgenic mouse model for human DC-SIGN, called hSIGN mouse, was used to test the potential of DC-SIGN-targeted vaccines in vivo. Antigen specific T-cell responses were analyzed by flow cytometry and antigen specific antibody as well as cytokine responses were measured by ELISA. Dependent on distinct DC-SIGN ligands we observed enhanced or decreased antigen specific T-cell responses. Consequently, DC-SIGN ligands might improve both immunity and tolerance. Furthermore, a BAC transgenic mouse for human TLR9, called HUT9 mouse, was generated and characterized on protein and DNA level. This mouse model will provide new information for the employment of TLR9 ligands in human immunotherapy.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI